Literature DB >> 21395349

Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Henry A Glick1.   

Abstract

Sample size and power for cost-effectiveness analysis depend on assumptions about the difference in cost and effect, the standard deviations of cost and effect, the correlation of the difference in cost and effect, the α and β errors and maximum willingness to pay (W). The first seven of these parameters share much in common in their effect on sample size and power for cost-effectiveness analysis, including that each is associated with a single pattern of power. W, on the other hand, is unique in that, when plotted for positive values, we can potentially observe any of six patterns of power associated with positive values of W. In addition, as W approaches ∞, power need be neither monotonically increasing nor decreasing and it can be multimodal. In this article, the relationship between W and sample size and power is explained.

Mesh:

Year:  2011        PMID: 21395349     DOI: 10.2165/11585080-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

Review 1.  What is the price of life and why doesn't it increase at the rate of inflation?

Authors:  Peter A Ubel; Richard A Hirth; Michael E Chernew; A Mark Fendrick
Journal:  Arch Intern Med       Date:  2003-07-28

2.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.

Authors:  Nancy Devlin; David Parkin
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

3.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

Authors:  Hans-Georg Eichler; Sheldon X Kong; William C Gerth; Panagiotis Mavros; Bengt Jönsson
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

4.  Health economics: Life in the balance.

Authors:  Daniel Cressey
Journal:  Nature       Date:  2009-09-17       Impact factor: 49.962

5.  Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

6.  Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Authors:  Konstantin J Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D Szucs
Journal:  Eur J Cancer       Date:  2009-01-13       Impact factor: 9.162

  6 in total
  10 in total

1.  Cognitive behavioral therapy for insomnia in stable heart failure: Protocol for a randomized controlled trial.

Authors:  Nancy S Redeker; Andrea K Knies; Christopher Hollenbeak; H Klar Yaggi; John Cline; Laura Andrews; Daniel Jacoby; Anna Sullivan; Meghan O'Connell; Joanne Iennaco; Lisa Finoia; Sangchoon Jeon
Journal:  Contemp Clin Trials       Date:  2017-01-31       Impact factor: 2.226

2.  Sample size and power for cost-effectiveness analysis (part 1).

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

3.  Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

4.  Cost Effectiveness of the Use of Prophylactic Mesh To Prevent Parastomal Hernia After Urinary Diversion with an Ileal Conduit.

Authors:  Sanjib Saha; Ulf Gerdtham; Mats Bläckberg; Petter Kollberg; Fredrik Liedberg
Journal:  Eur Urol Open Sci       Date:  2022-04-21

5.  Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?

Authors:  Elise Chia-Hui Tan; Raoh-Fang Pwu; Duan-Rung Chen; Ming-Chin Yang
Journal:  Qual Life Res       Date:  2013-08-23       Impact factor: 4.147

6.  A culturally adapted lifestyle intervention addressing a Middle Eastern immigrant population at risk of diabetes, the MEDIM (impact of Migration and Ethnicity on Diabetes In Malmö): study protocol for a randomized controlled trial.

Authors:  Sanjib Saha; Matti Leijon; Ulf Gerdtham; Kristina Sundquist; Jan Sundquist; Daniel Arvidsson; Louise Bennet
Journal:  Trials       Date:  2013-09-03       Impact factor: 2.279

7.  Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India: an application of the net-benefit regression framework.

Authors:  Samuel D Shillcutt; Amnesty E LeFevre; Christa L Fischer-Walker; Sunita Taneja; Robert E Black; Sarmila Mazumder
Journal:  Cost Eff Resour Alloc       Date:  2017-06-08

8.  Structured physiotherapy including a work place intervention for patients with neck and/or back pain in primary care: an economic evaluation.

Authors:  Sanjib Saha; Birgitta Grahn; Ulf-G Gerdtham; Kjerstin Stigmar; Sara Holmberg; Johan Jarl
Journal:  Eur J Health Econ       Date:  2018-08-31

9.  Randomised clinical trial for the cost-utility evaluation of two strategies of perineal reconstruction after abdominoperineal resection in the context of anorectal carcinoma: biological mesh repair versus primary perineal wound closure, study protocol for the GRECCAR 9 Study.

Authors:  Etienne Buscail; Cindy Canivet; Laurent Ghouti; Sylvain Kirzin; Nicolas Carrere; Laurent Molinier; Aline Rosillo; Valerie Lauwers-Cances; Nadège Costa
Journal:  BMJ Open       Date:  2021-04-01       Impact factor: 2.692

10.  Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance.

Authors:  William Sones; Steven A Julious; Joanne C Rothwell; Craig Robert Ramsay; Lisa V Hampson; Richard Emsley; Stephen J Walters; Catherine Hewitt; Martin Bland; Dean A Fergusson; Jesse A Berlin; Doug Altman; Luke David Vale; Jonathan Alistair Cook
Journal:  Trials       Date:  2018-10-10       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.